Janney Montgomery Scott LLC Boosts Stock Position in Enovis Corporation $ENOV

Janney Montgomery Scott LLC increased its stake in Enovis Corporation (NYSE:ENOV) by 2.7% during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 22,375 shares of the company’s stock after buying an additional 593 shares during the period. Janney Montgomery Scott LLC’s holdings in Enovis were worth $702,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in ENOV. Farther Finance Advisors LLC grew its stake in shares of Enovis by 266.7% in the 1st quarter. Farther Finance Advisors LLC now owns 737 shares of the company’s stock worth $27,000 after buying an additional 536 shares during the last quarter. GAMMA Investing LLC grew its stake in shares of Enovis by 144.8% in the 1st quarter. GAMMA Investing LLC now owns 1,170 shares of the company’s stock worth $45,000 after buying an additional 692 shares during the last quarter. DekaBank Deutsche Girozentrale grew its stake in shares of Enovis by 57.7% in the 1st quarter. DekaBank Deutsche Girozentrale now owns 1,981 shares of the company’s stock worth $74,000 after buying an additional 725 shares during the last quarter. Cullen Frost Bankers Inc. purchased a new stake in shares of Enovis in the 1st quarter worth approximately $198,000. Finally, McIlrath & Eck LLC grew its stake in shares of Enovis by 52.2% in the 1st quarter. McIlrath & Eck LLC now owns 5,274 shares of the company’s stock worth $202,000 after buying an additional 1,808 shares during the last quarter. Hedge funds and other institutional investors own 98.45% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have commented on ENOV. Weiss Ratings reiterated a “sell (d-)” rating on shares of Enovis in a research note on Wednesday, October 8th. UBS Group cut their target price on Enovis from $65.00 to $57.00 and set a “buy” rating on the stock in a research note on Friday, August 8th. Wells Fargo & Company cut their target price on Enovis from $48.00 to $41.00 and set an “overweight” rating on the stock in a research note on Friday, August 8th. Needham & Company LLC cut their target price on Enovis from $57.00 to $49.00 and set a “buy” rating on the stock in a research note on Thursday, August 7th. Finally, Evercore ISI cut their target price on Enovis from $48.00 to $46.00 and set an “outperform” rating on the stock in a research note on Tuesday, July 8th. Six analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $51.00.

Enovis Price Performance

Shares of Enovis stock opened at $31.16 on Thursday. Enovis Corporation has a one year low of $25.47 and a one year high of $49.83. The stock’s fifty day moving average is $30.76 and its 200 day moving average is $31.67. The stock has a market cap of $1.78 billion, a P/E ratio of -2.19 and a beta of 1.69. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.15 and a current ratio of 2.25.

Enovis (NYSE:ENOV) last announced its earnings results on Monday, January 8th. The company reported $0.59 EPS for the quarter. Enovis had a positive return on equity of 6.78% and a negative net margin of 37.80%.The company had revenue of $383.81 million for the quarter. Sell-side analysts anticipate that Enovis Corporation will post 2.79 earnings per share for the current year.

Insider Buying and Selling

In related news, CEO Damien Mcdonald bought 6,457 shares of the firm’s stock in a transaction that occurred on Thursday, September 11th. The shares were bought at an average cost of $30.97 per share, with a total value of $199,973.29. Following the acquisition, the chief executive officer owned 102,753 shares in the company, valued at $3,182,260.41. This trade represents a 6.71% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Phillip Benjamin (Ben) Berry purchased 2,500 shares of the firm’s stock in a transaction on Wednesday, August 20th. The shares were acquired at an average cost of $29.71 per share, for a total transaction of $74,275.00. Following the completion of the acquisition, the chief financial officer owned 116,729 shares of the company’s stock, valued at approximately $3,468,018.59. This trade represents a 2.19% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last three months, insiders have purchased 12,157 shares of company stock valued at $374,760. 2.70% of the stock is owned by company insiders.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.